IMC Stock Overview A biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Immuron Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Immuron Historical stock prices Current Share Price AU$0.078 52 Week High AU$0.17 52 Week Low AU$0.065 Beta 1.19 1 Month Change -1.27% 3 Month Change -22.00% 1 Year Change 4.00% 3 Year Change -25.71% 5 Year Change -42.22% Change since IPO -58.03%
Recent News & Updates
Immuron Limited, Annual General Meeting, Nov 18, 2024 Oct 18
Immuron Limited Announces NMRC Reports Results for Campylobacter Clinical Study Oct 04
Full year 2024 earnings released: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023) Oct 03
Full year 2024 earnings released: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023) Aug 31 Immuron Limited has filed a Follow-on Equity Offering in the amount of $2.069083 million. Jul 04
Immuron Requests Pre-IND Meeting for IMM-529 with FDA Filing Jul 02 See more updates
Immuron Limited, Annual General Meeting, Nov 18, 2024 Oct 18
Immuron Limited Announces NMRC Reports Results for Campylobacter Clinical Study Oct 04
Full year 2024 earnings released: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023) Oct 03
Full year 2024 earnings released: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023) Aug 31 Immuron Limited has filed a Follow-on Equity Offering in the amount of $2.069083 million. Jul 04
Immuron Requests Pre-IND Meeting for IMM-529 with FDA Filing Jul 02
Immuron Limited Appoints Jeannette Joughin as Director Jun 06
Immuron Limited Announces Resignation of Roger Aston as Non-Executive Director May 31
Immuron Limited Announces Positive Results Support Travelan Progress to Phase 3 Clinical Trials in the US Mar 07
Immuron Limited Clinical Trials Update Dec 22
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study Dec 04
Immuron Limited, Annual General Meeting, Nov 21, 2023 Oct 23
Immuron Limited Announces Travelan® Clinical Study Cohort 2 Commences Oct 19
Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.013 loss in FY 2022) Oct 01
Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.013 loss in FY 2022) Aug 30
New major risk - Share price stability Aug 10
Immuron Limited Announces First Patients Enrolled in Travelan® Clinical Study Jul 26
Immuron Limited Initiates Recruitment of Travelan Clinical Study May 31
Immuron Limited Announces US Food and Drug Administration Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves Way for Clinical Trial Initiation May 09
First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.008 loss in 1H 2022) Mar 03
Immuron US DoD Naval Medical Research Center Responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic Jan 25
Immuron Limited Receives FDA Approval for Travelan IND Application Dec 23
Immuron Limited Submits IND Application To FDA for Travelan Dec 05
Insufficient new directors Nov 23
Immuron Limited, Annual General Meeting, Oct 28, 2022 Oct 14
Full year 2022 earnings released: AU$0.013 loss per share (vs AU$0.038 loss in FY 2021) Sep 02
Immuron Limited Provides Update on IMM-124E SARS-CoV-2 Research Aug 19
Insufficient new directors Aug 16
Immuron Limited Provides Update on IND Application for Campylobacter ETEC Therapeutic Jul 26
Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic May 12
Immuron Limited Provides Update on the Planned Clinical Trial to Evaluate the Efficacy of Travelan and Two Third Party Non-Antibiotic Products in Travelers' Diarrhea May 09 Immuron Limited Appoints Steven Lydeamore as Chief Executive Officer, effective June 27, 2022
Insufficient new directors Apr 27
Immuron Limited Announces Work on the Investigational New Drug Application to Evaluate the Efficacy of A Single Dose Regimen of Travelan Apr 19
First half 2022 earnings: Revenues and EPS in line with analyst expectations Mar 02
Full year 2021 earnings released: AU$0.038 loss per share (vs AU$0.017 loss in FY 2020) Oct 04
Executive Vice Chairman Peter Anastasiou has left the company Oct 03
Insufficient new directors Sep 25
Immuron Limited Provides Monash University Research Update on SARS-CoV-2 Program May 15
First half 2021 earnings released: AU$0.026 loss per share (vs AU$0.009 loss in 1H 2020) Mar 02
New 90-day low: AU$0.21 Feb 02
New 90-day low: AU$0.21 Jan 04
Immuron Limited Provides Update on Progress of the Anti-Viral Activity of IMM-124E Dec 15
Immuron Limited Announces That the Naval Medical Research Center Has Completed the Characterisation of the Colostrum Harvested from Cows Immunized with the Experimental Vaccine Developed to Target Campylobacter and Enterotoxigenic E.Coli Nov 12
Immuron Limited Announces US DoD NMRC Reports Positive Response to Vaccine Nov 09
New 90-day low: AU$0.23 Nov 03
Immuron Limited Provides Shareholders and the Market with an Update on the Planned Clinical Programs in Travelers’ Diarrhea Oct 13
Full year earnings released - AU$0.017 loss per share Sep 02 Immuron Limited has completed a Follow-on Equity Offering in the amount of $20.000025 million.
New 90-day high - AU$0.87 Jul 21 Shareholder Returns IMC AU Biotechs AU Market 7D -1.3% 0.5% -0.09% 1Y 4.0% 3.4% 8.3%
See full shareholder returns
Return vs Market: IMC underperformed the Australian Market which returned 7.4% over the past year.
Price Volatility Is IMC's price volatile compared to industry and market? IMC volatility IMC Average Weekly Movement 7.6% Biotechs Industry Average Movement 9.8% Market Average Movement 7.9% 10% most volatile stocks in AU Market 16.7% 10% least volatile stocks in AU Market 3.0%
Stable Share Price: IMC has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: IMC's weekly volatility has decreased from 18% to 8% over the past year.
About the Company Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers’ diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver.
Show more Immuron Limited Fundamentals Summary How do Immuron's earnings and revenue compare to its market cap? IMC fundamental statistics Market cap AU$17.87m Earnings (TTM ) -AU$6.94m Revenue (TTM ) AU$4.90m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) IMC income statement (TTM ) Revenue AU$4.90m Cost of Revenue AU$1.57m Gross Profit AU$3.34m Other Expenses AU$10.27m Earnings -AU$6.94m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.03 Gross Margin 68.06% Net Profit Margin -141.49% Debt/Equity Ratio 0%
How did IMC perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 15:30 End of Day Share Price 2025/01/02 00:00 Earnings 2024/06/30 Annual Earnings 2024/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Immuron Limited is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Dennis Hulme APP Securities Pty Ltd. Raghuram Selvaraju H.C. Wainwright & Co. Sally Yanchus Litchfield Hills Research, LLC
Show 0 more analysts 
